Concord Medical Services, the operator of China's largest network of cancer treatment centres, has started to accept orders for an initial public offering that aims to raise between $114 million and $138 million. The Beijing-based company is expected to start trading on the New York Stock Exchange towards the end of next week.
Concord will provide an opportunity for international investors to get exposure to a Chinese healthcare company that operates at the patient level. So far, investors have been able to invest in companies involved in pharmaceuticals or the provision of medical equipment, but not the actual treatment of patients. The last Chinese company in the healthcare sector to go public was Sinopharm, a...
¬ Haymarket Media Limited. All rights reserved.
